` LABB (Genomma Lab Internacional SAB de CV) vs Mexico S&P/BMV IPC Comparison - Alpha Spread

LABB
vs
Mexico S&P/BMV IPC

Over the past 12 months, LABB has significantly outperformed Mexico S&P/BMV IPC, delivering a return of 33% compared to the Mexico S&P/BMV IPC's 9% growth.

Stocks Performance
LABB vs Mexico S&P/BMV IPC

Loading
LABB
Mexico S&P/BMV IPC
Add Stock

Performance Gap
LABB vs Mexico S&P/BMV IPC

Loading
LABB
Mexico S&P/BMV IPC
Difference
www.alphaspread.com

Performance By Year
LABB vs Mexico S&P/BMV IPC

Loading
LABB
Mexico S&P/BMV IPC
Add Stock

Competitors Performance
Genomma Lab Internacional SAB de CV vs Peers

Mexico S&P/BMV IPC
LABB
LLY
JNJ
NOVO B
ROG
Add Stock

Genomma Lab Internacional SAB de CV
Glance View

Market Cap
21.5B MXN
Industry
Pharmaceuticals

Nestled amid the dynamic landscape of the Mexican pharmaceutical and personal care market, Genomma Lab Internacional SAB de CV has carved a distinct niche for itself since its inception in 1996. The company, recognized for its innovative approach to marketing and product distribution, operates with a dual business model that focuses both on over-the-counter (OTC) medications and a slew of personal care products. This strategic diversification has enabled Genomma Lab to tap into a broad array of consumer needs, expanding its reach beyond the confines of Mexico to a wide array of markets across the Latin American region and beyond. By leveraging a robust distribution network, which includes traditional retailers and modern trade channels, Genomma ensures that its products – from headache remedies to skincare solutions – are easily accessible to consumers, thereby driving consistent revenue growth. Central to Genomma Lab's success is its ability to blend strategic marketing prowess with an agile supply chain. The company's marketing campaigns are meticulously crafted, often highlighting the efficacy and trustworthiness of its products, which resonates well with a cost-sensitive yet quality-oriented consumer base. Furthermore, Genomma Lab thrives on an innovative product pipeline that sees continual introductions and adaptations in response to changing market demands. This commitment to innovation is complemented by cost efficiency in its operations, allowing the company to maintain competitive pricing. With an entrenched brand presence and a solid track record of adaptability, Genomma Lab continues to bolster its market position, focusing on both organic growth and strategic alliances to propel its evolution in the global marketplace.

LABB Intrinsic Value
31.2 MXN
Undervaluation 29%
Intrinsic Value
Price
Back to Top